Inogen (INGN) Capital Expenditures Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 10.17% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 1.81% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2.15% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 0.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.35% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 8.08% |
| 10 | Inogen | 165.85 Mn | 71.44 Mn | 37.86 Mn | 47.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.83% |
| Dec 31, 2025 | -56.14% |
| Sep 30, 2025 | 24.66% |
| Jun 30, 2025 | -31.68% |
| Mar 31, 2025 | 47.50% |
| Dec 31, 2024 | 69.69% |
| Sep 30, 2024 | -28.02% |
| Jun 30, 2024 | -32.40% |
| Mar 31, 2024 | 157.19% |
| Dec 31, 2023 | -76.56% |
| Sep 30, 2023 | 4.98% |
| Jun 30, 2023 | 26.77% |
| Mar 31, 2023 | -64.71% |
| Dec 31, 2022 | -1.10% |
| Sep 30, 2022 | 0.57% |
| Jun 30, 2022 | 27.29% |
| Mar 31, 2022 | -53.97% |
| Dec 31, 2021 | -55.92% |
| Sep 30, 2021 | 31.56% |
| Jun 30, 2021 | 12.56% |
| Mar 31, 2021 | -66.65% |
| Dec 31, 2020 | 35.96% |
| Sep 30, 2020 | 18.43% |
| Jun 30, 2020 | -44.70% |
| Mar 31, 2020 | 35.61% |
| Dec 31, 2019 | 136.92% |
| Sep 30, 2019 | -112.58% |
| Jun 30, 2019 | 26.64% |
| Mar 31, 2019 | 9.33% |
| Dec 31, 2018 | 44.88% |
| Sep 30, 2018 | -60.94% |
| Jun 30, 2018 | -30.06% |
| Mar 31, 2018 | 55.49% |
| Dec 31, 2017 | -82.71% |
| Sep 30, 2017 | 61.64% |
| Jun 30, 2017 | -44.45% |
| Mar 31, 2017 | 51.96% |
| Dec 31, 2016 | -19.94% |
| Sep 30, 2016 | 27.03% |
| Jun 30, 2016 | -51.84% |
| Mar 31, 2016 | -39.11% |